NanoVibronix, Inc. (NAOV)

NASDAQ: NAOV · IEX Real-Time Price · USD
0.940 -0.019 (-1.98%)
Jan 18, 2022 10:19 AM EST - Market open

Company Description

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy.

Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing.

The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally.

NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.

NanoVibronix, Inc.
NanoVibronix Logo
CountryUnited States
Founded2003
IndustryHealth Care Equipment & Supplies
SectorHealth Care
Employees11
CEOBrian Murphy

Contact Details

Address:
525 Executive Blvd
Elmsford, New York 10523-1240
United States
Phone914 233 3004
Websitenanovibronix.com

Stock Details

Ticker SymbolNAOV
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001326706

Key Executives

NamePosition
Brian M. MurphyChief Executive Officer and Director
Stephen R. Brown CPA, CPAChief Financial Officer and Accounting Officer
Amir RippelVice President of Marketing
Mrs. Lindsey HarrisonVice President of Sales
Dr. Harold Jacob M.D.Chief Medical Officer and Director

Latest SEC Filings

DateTypeTitle
Jan 3, 20224Statement of changes in beneficial ownership of securities
Jan 3, 20224Statement of changes in beneficial ownership of securities
Jan 3, 20224Statement of changes in beneficial ownership of securities
Jan 3, 20224Statement of changes in beneficial ownership of securities
Dec 30, 20218-KCurrent report
Dec 30, 20214Statement of changes in beneficial ownership of securities
Dec 30, 20214Statement of changes in beneficial ownership of securities
Dec 30, 20214Statement of changes in beneficial ownership of securities
Dec 21, 2021DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 16, 2021DEF 14AOther definitive proxy statements
View All SEC Filings